After taking a PhIII thrashing, AstraZeneca comes out swinging with breakthrough titles, new cancer hires
AstraZeneca $AZN may be down, but it’s not out.
Sent reeling over the failure of its first big primary endpoint for a checkpoint combo of durvalumab and tremelimumab late last week, the pharma giant reports it just scored the FDA’s breakthrough drug designation for acalabrutinib as a treatment for mantle cell lymphoma, its second breakthrough title in two days.
The BTD for acalabrutinib came fast on the heels of the breakthrough title for durvalumab for unresectable non-small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.